However, the pure fact that PHD3 is highly overexpressed in human tumour specimens raises the question, whether PHD3 may represent a suitable target for therapeutic intervention against pancreatic cancer as its overexpression caused a dramatic suppression of tumour growth in experimental pancreatic cancer. The gene discussed is EGLN3; the disease is neoplasm.